Project Grant W81XWH1510541

This Cooperative Agreement award for $310,185.00 from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports research by New York University School of Medicine to analytically and clinically validate an Epic 900K V2 array-based methylation assay for predicting recurrence in stage II melanoma. The project aims to refine and validate a 13-probe signature that was previously found to accurately identify melanoma recurrence and mortality among stage II...

The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $799,107 Project Grant to the Dana-Farber Cancer Institute, Inc. in Boston, MA to conduct research on using genomic biomarkers and decision analysis frameworks to guide treatment decisions for stage III melanoma patients. The grant will fund a collaborative project involving researchers from Dana-Farber and Brigham & Women's Hospital to develop methods for translating genomic and...

This $412,054 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support research at New York University (NYU) to dissect the role of the immune microenvironment in melanoma bone metastasis. The funded research aims to utilize preclinical murine models to define the mechanisms by which melanoma cells colonize the skeletal system and modify the bone microenvironment. Key objectives include examining the role of bone...

This Cooperative Agreement award from the National Cancer Institute, a division of the Department of Health and Human Services, provides $380,509 under the Cancer Biology Research program to The Trustees of Columbia University in New York. The award supports research to elucidate the molecular drivers of melanoma liver metastasis and associated resistance to immunotherapies. Specifically, the researchers will characterize a novel preclinical mouse model that recapitulates genomic and...

The University of Virginia received a $921,351 project grant award on September 30, 2023 from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to support research on "APPROACHES TO ENHANCE VACCINE-INDUCED TUMOR-INFILTRATING LYMPHOCYTES (VITILS) IN MELANOMA". This multi-year grant, scheduled for completion on September 29, 2026, aims to advance biomedical research that can transform healthcare for Service Members and the American public. The...

The U.S. Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), has awarded a $947,746 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) to conduct research on "IDENTIFICATION OF THE LIVER MICROENVIRONMENT THAT DRIVES UVEAL MELANOMA METASTASIS AND IMMUNITY". The 3-year grant, beginning on September 1, 2024 and ending on August 31, 2027, will enable DFCI, a non-profit cancer research center in Boston, MA, to investigate the liver...

The University of Michigan received a $210,600 Cooperative Agreement award from the National Cancer Institute's (CFDA 93.394) Cancer Detection and Diagnosis Research program. The project aims to analytically validate and clinically evaluate an H3K27M circulating tumor DNA (ctDNA) assay to monitor patients with diffuse midline gliomas (DMGs), a type of brain tumor with a very poor prognosis. The objectives are to: 1) analytically validate the H3K27M ctDNA plasma assay as a CLIA-compliant...

This $693,642 federal Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports research at the University of Virginia to enhance vaccine-induced tumor-infiltrating lymphocytes (VITILS) in melanoma. The 3-year research project aims to develop innovative approaches to boost the effectiveness of cancer immunotherapies by improving the ability of T cells to infiltrate and attack melanoma tumors. Key deliverables will include...

This Project Grant award, titled "NKG7-ARMED TUMOR-INFILTRATING LYMPHOCYTE THERAPY FOR METASTATIC UVEAL MELANOMA," was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The $2,455,718 award to the Mayo Clinic in Rochester, Minnesota, supports advanced biomedical research aimed at developing innovative tumor-infiltrating lymphocyte (TIL) therapy for the treatment of metastatic uveal melanoma. This 4-year project, running...

The National Cancer Institute awarded a $433,256 Project Grant under the Cancer Treatment Research (CFDA 93.395) program to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The grant supports a 2-year research project to investigate the role of an antisense RNA, CDH3-AS1, in suppressing melanocyte transformation and melanoma development. The project aims to develop genetic tools to modulate endogenous CDH3-AS1 expression and assess its tumor suppressive...